<DOC>
	<DOCNO>NCT00005952</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose temozolomide give peripheral stem cell transplantation see well work treat child newly diagnose malignant glioma recurrent CNS tumor solid tumor .</brief_summary>
	<brief_title>Temozolomide Plus Peripheral Stem Cell Transplantation Treating Children With Newly Diagnosed Malignant Glioma Recurrent CNS Other Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temozolomide child newly diagnose malignant glioma recurrent CNS solid tumor . - Evaluate toxicity treatment patient . - Determine activity treatment patient . OUTLINE : This dose escalation study temozolomide . Patients receive filgrastim ( G-CSF ) subcutaneously ( SQ ) IV begin day -5 continue least day 3 . Peripheral blood stem cell ( PBSC ) collect day 0 , 2 , 4 . Patients receive oral temozolomide daily 5 consecutive day . PBSC collection reinfused 1 day last dose temozolomide . Patients also receive G-CSF beginning time transplant continue blood count recover . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow every 3 month 1-3 year , annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study 12 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose malignant glioma recurrent malignant CNS tumor pathology OR Histologically confirm nonCNS tumor Recurrent soft tissue sarcoma ( e.g. , rhabdomyosarcoma ) Recurrent resistant neuroblastoma Recurrent Wilm 's tumor Recurrent Ewing 's sarcoma Recurrent primitive neuroectodermal tumor Recurrent nasopharyngeal carcinoma Recurrent germ cell tumor Expected cure rate le 10 % standard therapy Measurable and/or active disease History bone marrow tumor infiltration without mass lesion isolate abnormal CSF cytology evidence recurrent disease allow complete response first achieve primary conventional therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % OR Lansky 70100 % Life expectancy : Greater 8 week Hematopoietic : Reasonably cellular bone marrow ( great 15 % cellularity biopsy ) Absolute neutrophil count great 1,000/mm^3 Platelet count great 75,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGPT le 120 U/L Renal : Creatinine le 1.5 mg/dL Cardiovascular : Systolic fraction ejection fraction least 80 % predict age echocardiogram Pulmonary : CVC DLCO least 60 % predicted age OR clearance pulmonologist Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active infection Able tolerate vigorous hydration schedule PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent white blood cell transfusion No concurrent hematopoietic growth factor Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent cytotoxic drug ( systemic intrathecal ) Endocrine therapy : Concurrent corticosteroid allow Radiotherapy : See Disease Characteristics At least 1 week since prior radiotherapy Surgery : At least 1 week since prior surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage IV Wilms tumor</keyword>
	<keyword>stage V Wilms tumor</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
</DOC>